The connection between Cannabis sativa's chemical compounds and their ability to treat three different inflammatory ailments including bowel diseases, (IBD, e.g., Crohn's and ulcerative colitis), neuronal diseases (IND, e.g., Parkinson and Alzheimer), and a wide range of inflammatory skin diseases (ISD, e.g., atopic dermatitis and psoriasis) is presented. We review the range of experiments conducted over the last decade using either the whole extract of cannabis or separated mono-phytocannabinoids in the attempt to decipher the lead molecules, the receptors involved, the effects on genes and proteins, and especially the therapeutic potency of cannabis-derived compounds for treating these different inflammatory diseases. Along with the specifications for its current cuttingedge potential, the drawbacks and the designated needs for additional specific information from future research are indicated.
Besides its mind-altering properties, cannabis is also known to have many other effects on the human body, including alleviating pain and curing disease. Traditional and modern medical treatment by C. sativa suggests that this plant has the ability to offer relief for chronic neuropathic pain [11] [12] [13] , nausea, headaches and fatigue. This relief usually accounts for the psychotropic effect of the active compounds produced in the plant [3] . However, an increasing number of medical indications suggests that C. sativa's active compounds may also directly affect human cells and tissues and, thereby, have an independent therapeutic effect. Different research groups are studying the effects of exogenously applied cannabinoids in treating symptoms of epilepsy [14] , chemotherapy-induced nausea [15] , anorexia [16] , multiple sclerosis spasticity [17] [18] [19] [20] , fibromyalgia and rheumatoid arthritis [11] [12] [13] , glaucoma intraocular pressures [21] , and asthma-associated dyspnea [22] . Although the FDA recently approved a study on the effect of medical cannabis for treating military veterans with post-traumatic stress disorder and despite all of the cumulative knowledge on active compounds of cannabis and their therapeutic effects in in-vitro and in-vivo systems, cannabis is not yet perceived as a conventional medical therapy. The main reason for this perception may be that treatment is insufficiently specific and, as a result, along with the desired effects, the use of cannabis involves undesirable mind alteration.
Compounds produced by plants are called phytochemicals and are characterized by their diversity and are idiosyncratically distributed among plant families. C. sativa contains more than 600 different phytochemicals, among those about 120 characteristic terpenophenolic compounds commonly termed phytocannabinoids [2] (Figure  1 ). In the last decade, the number of identified phytocannabinoids has doubled [23, 2] . The most studied of these, dronabinol (Δ9-tetrahydrocannabinol, THC) and cannabidiol (CBD) have been defined as the most active of the phytocannbinoids [1, 24, 25] . These two compounds occur in high amounts in most cannabis strains, either with a predominance of one over the other or with relatively equal amounts. This relative amount allows a differentiation between two main groups, one mostly diagnosed as "high in THC", which are related to sativa-originated strains and the other, "high in CBD" that are more indica-related strains [26] . However, over the last decade, many more phytocannabinoids were identified and their structure was more thoroughly studied [2, [26] [27] [28] . Besides phytocannabinoids, more than 400 other phytochemicals have been identified to date in C. sativa [29] the most predominant among them are hydrocarbons, terpenes, flavonoids and primary metabolites.
Two types of G-protein-coupled cannabinoid receptors were identified: cannabinoid Type 1 (CB1, cloned in 1990) and cannabinoid Type 2 (CB2, cloned in 1993) [30, 31] . Cannabinoid receptors are distributed mainly in the central nervous system (CNS), but also in other peripheral tissues including the spleen, the reproductive, urinary and gastrointestinal tracts, the endocrine glands, the arteries and the heart [32] . The existence of additional cannabinoid receptor subtypes was investigated [33] [34] [35] [36] .
The function of the different phytochemicals in the different curing processes is not fully understood, but their significant role is beginning to be appreciated [37] . In this review, however, we will focus solely on the effects of phytocannabinoids, especially their anti-inflammatory activity, highlighting their ability to act as therapeutic agents against inflammation while presenting the pros and cons of potential strategies that can be used to this end.
Cannabis in the treatment of inflammatory bowel diseases (IBD): Inflammatory bowel diseases (IBD), namely Crohn's disease (CD) and ulcerative colitis (UC), are usually characterized by chronic intestinal inflammation [38] . Both diseases are associated with different mutation backgrounds. Although these diseases are both relapsing, their reactivation is triggered by environmental factors. In this case, a breakdown of the mucosal barrier alters the balance between beneficial and pathogenic enteric bacteria. This imbalance, consequently, stimulates immune responses, either innate (macrophage, neutrophil) or acquired (T and B cell) [39] .
Epithelial cells in the gastrointestinal tract prevent the absorption of potentially harmful substances and microorganisms in the intestinal lumen and, thus, play an important role in inflammatory responses. Epithelial cells express pro-inflammatory cytokines, which are usually upregulated in IBD patients [40] . Therapies aimed at depressing intestinal inflammation use immune suppression, both specifically and nonspecifically mediated. However, potentially, this approach bears considerable side effects [41] .
Cannabinoids have been previously shown to be immune modulators [42] . Cannabinoids shift the balance of pro-and antiinflammatory cytokines and act to suppress cell-mediated immunity in different physiological systems [43] . Moreover, two clinical trials demonstrated the beneficial effects of cannabis for IBD patients. One was a retrospective study based on interviews with 30 CD patients who were licensed to use medical cannabis [44] . The other consisted of two double-blind, placebo-controlled trials investigating the effects of cannabinoids on patients with IBD [45] . Notably, patients with CD who did not respond to conventional therapy, but were given cannabis, achieved complete remission 5 times more than IBDs patients treated with placebo [45] . Naftali et al [45] reported a clinical response (decrease in CDAI score of >100) in 90% of those CD patients given cannabis over only 40% from those who were not. Several patients given cannabis were even weaned from steroid dependency. That IBD patients given cannabis reported no significant side effects is also important.
Phytocannabinoids have been shown to exert their biological functions on the gastrointestinal (GI) tract by mainly CB1 and CB2 [46, 47] . Later, GPR55, a third cannabinoid receptor involved in GI inflammation was also identified [48, 49] . These receptors are part of the endocannabinoid system in the GI tract [49, 50] .
Among the known phytocannabinoids, CBD is mostly appreciated for the treatment of IBD [51] . The mode of action of CBD is not fully understood and at least four different mechanisms have been proposed [52] [53] [54] [55] [56] [57] . However, while these mechanisms were demonstrated on mice, they showed no or minimal effect on humans [58, 59] . Indeed, cannabinoids have been shown to be effective in a mouse model of colitis [60] [61] [62] . For example, Borrelli et al [63] investigated the effect of pure cannabigerol (CBG), another nonpsychotropic cannabinoid, in a murine model of colitis (induced by 2,4,6-dinitrobenzene sulphonic acid, DNBS). After inducing inflammation, supplementation of CBG to the mice led to a reduction of inflammation, CuZn-superoxide dismutase activity increased and reduced changes in the levels of interleukin-1β, interleukin-10 and interferon-γ associated with DNBS administration. In murine macrophages, CBG reduced nitric oxide production (the effect being modulated by the CB2 receptor) and reduced formation of reactive oxygen species in intestinal epithelial cells.
In the human colonic epithelial HT29 cell line, a number of cannabinoid receptor agonists and antagonists, including the plantderived THC, have been shown to inhibit tumor necrosis factor alpha (TNFα)-induced interleukin-8 (IL-8) release [64] . This inhibition was antagonized by CB2 receptor antagonist [46] . Cannabinoids have also been shown to promote wound healing in the GI tract via CB1 receptor activation [46, 47] . In addition, we have shown recently that when purified from the plant, Δ9-Tetrahydrocannabinolic Acid (THCA), is the lead molecule in alleviating inflammation in several colon cell lines and colon tissues of IBD patients [65] .
To conclude, C. sativa and derived cannabinoids produce beneficial effects for patients with IBDs. It is still unclear whether cannabis can induce remission in patients with Crohn's disease. Also, larger patient groups require testing in order to conclude on an acceptable therapy. In addition, a non-smoking mode of intake is highly desirable, in order to obtain a designated therapy that will reach the desired malfunctioning areas along the gut.
Cannabis in the treatment of inflammatory neuronal diseases (IND): Parkinson and Alzheimer:
Parkinson's disease (PD) is a chronic, progressive neurodegenerative disorder [16] . In PD, dopamine (DA)-containing neurons of the substantia nigra (controlling also movement) are being degenerated, leading to severe DAergic denervation of the striatum (the part of the brain that controls movement pathways among other cognitive abilities). This irreversible damage leads to the typical motor symptoms observed in patients suffering from Parkinson, such as bradykinesia, tremor, and rigidity [66] .
Studies showed that CB1 receptor antagonists could be useful in the treatment of PD symptoms [67] . Furthermore, high levels of endogenous cannabinoid were detected in the cerebrospinal fluid of untreated PD patients [68] . Thus, administration of inhibitors of endocannabinoid degradation reduced Parkinsonian motor deficits [69] . In clinical trials, it was demonstrated that the cannabinoid receptor agonist nabilone significantly reduced dyskinesia in Parkinson patients [70] . In contrast to these positive findings, some studies reported that no improvement was detected by oral administration of cannabis extract on PD symptoms [71] . It seems that cannabinoids may be able to treat some symptoms of neurological diseases [72, 73] , but not yet to a sufficient or reliable degree.
In fact, C. sativa has proven effective in maintaining three different aspects of PD. The first observed phenomenon is that cannabinoidrelated compounds were detected as useful in easing some
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Natural Product Communications Vol. 13 (3) 2018 251 symptoms of the disease. Another effect of cannabinoid-based compounds is their ability to protect against the progression of neuronal injury characteristic of PD. Cannabinoids also influence local inflammatory events associated with the pathogenesis in Parkinson disease [73] . The cannabinoid signaling system experiences a biphasic pattern of changes during the progression of PD [74] . Early stages of PD, which are pre-symptomatic, are characterized by neuronal malfunctioning where only little evidence of neuronal death are reported. This stage is associated with low reactivity of CB1 receptors. By contrast, as PD advances, it is characterized by a profound nigral degeneration and the occurrence of major Parkinsonian symptoms. This degradation is associated with up-regulatory responses of CB1 and possibly CB2 receptors as well as the endocannabinoid ligands for both receptors. This effect on the receptors would explain the motor inhibition typical of PD. Certain cannabinoids have demonstrated ability to reduce oxidative injury, excitotoxicity, calcium influx and glial activation. Therefore, the cannabinoid agonists that cooperatively contribute to the degeneration of nigral neurons have been proposed to serve as neuroprotective molecules in PD.
Alzheimer's disease (AD) is one of the leading causes of dementia among the elderly [75] . The most significant effect of AD is the damage caused to the cholinergic system. One of the primary neuropathological hallmarks of AD is deposition of Acetylcholine (AChE)-induced amyloid β-peptide (Aβ) into amyloid plaques in areas of the brain important for memory and cognition [76] . Studies conducted over the last two decades yielded various therapeutic strategies such as preventing downstream neurotoxic events, treating inflammation and intervening with Aβ metabolism [77] .
AChE acts as a molecular chaperone, accelerating the formation of amyloid fibrils in the brain. This causes the formation of stable complexes with Aβ which aggregates at the peripheral anionic binding site (PAS) [78] [79] [80] . In order to withhold this undesired aggregation from occurring, it was demonstrated that compounds containing rigid, aromatic scaffolds manage to interfere with the built of the protein-protein interactions in AChE PAS [81, 82] . THC, with its fused tricyclic lipophilic structure, can bind to the allosteric PAS of AChE and, thus, prevent AChE-promoted Aβ aggregation [83] . Studies of the THC-AChE interaction showed that THC binds to the peripheral anionic site of AChE, the critical region involved in amyloid genesis. THC prevents neurotransmitter degradation and reduces Aβ aggregation and, therefore, may directly affect the progression of AD.
To conclude, animal or cellular models demonstrate that cannabinoids have the therapeutic potential to treat basal ganglia diseases and other neurodegenerative disorders. However, in order to achieve a significant development in this field, clinical trials are still needed. Given the indications for the capability of cannabinoids to serve as neuroprotective agents against oxidative, inflammatory and other cytotoxic injuries, it would be beneficial that cannabinoid compound(s) compositions be subjected to clinical evaluation in HD or PD. It is likely that specific combination of cannabinoid compounds may be needed to optimally treat those difficult diseases, as the combination of cannabis-derived compounds is suspected to have a synergic effect that is important for the treatment of complex-sourced diseases.
Cannabis in the treatment of inflammatory skin diseases (ISD):
The endocannabinoid system (ECS) has demonstrated to have multiple regulatory functions, both in health and disease. Several studies suggested that the main physiological function of the cutaneous ECS is to constitutively control the proper and wellbalanced proliferation, differentiation and survival, as well as immune competence of skin cells [84] [85] [86] [87] . The disruption of the delicate balance of the endocannabinoid system might facilitate the development of multiple pathological conditions of the skin such as acne, seborrhea, atopic dermatitis, psoriasis, systemic sclerosis and cancer [85] . Therefore, normalizing the ECS might treat multiple human skin diseases. Psoriasis is a skin inflammation characterized by an accelerated turnover of epidermal keratinocyte proliferation. It was reported that cutaneous ECS inhibits cell growth and induces apoptosis in most of the skin cell types [81, 82] . Both human nonmelanoma and melanoma tumors express considerable amounts of CB1 and CB2 [84, 88, 89] . Atopic dermatitis is another skin inflammation. A pilot study carried out on 20 pediatric patients suffering from atopic dermatitis demonstrated the efficacy of a topical emulsion containing an endocannabinoids analog that showed dramatic increase in symptom resolution [90, 91] . Another experimental study has suggested that CB2 agonists could represent a promising approach for the treatment of early inflammatory stages of systemic sclerosis (scleroderma) [92] .
While endocannabinoid signalling has been shown to have a role in the control of epidermal physiology [86] , other studies showed that anandamide, an endocannabinoid, is able to regulate the expression of skin differentiation genes through DNA methylation. Investigation of the epigenetic regulation of these genes by specific phytocannabinoids showed that cannabidiol (CBD) and cannabigerol (CBG), when purified from the plant, significantly reduced the expression of all the genes tested in differentiated HaCaT cells, by increasing DNA methylation of keratin 10 gene (KRT10) [93] . Other phytocannabinoids tested (i.e., cannabidivarin) were ineffective. Moreover, CBD reduced KRT10 mRNA through CB1 -related mechanism and increased global DNA methylation levels, whereas CBG did not show similar effect on HaCaT cells [93] .These findings show that specific phytocannabinoids can control skin cell proliferation and differentiation [93] . This indicates that plant-derived CBG and especially CBD have the potential to be leading compounds for the development of novel therapeutics for skin diseases.
Summary:
Comparison between the effects of cannabis on the three different inflammation-related syndromes exhibited here (IBD, IND, ISD) show that cannabis-derived cannabinoids may affect different syndromes via different receptors and incompletely understood pathways. In addition, despite all three syndromes being closely associated with inflammation, different cannabinoids were found to be efficient for treatment, pointing to a need for specificity as to which cannabinoid should be used for a particular syndrome. Moreover, a combination between cannabinoids and other cannabisderived compounds has hardly been examined and should be further investigated.
One of the main problems with cannabis treatment is the elaborately argued psychoactive side effects. This undesired side effect of the cannabis whole extract is a major drawback, which sometimes even thwarts the beneficial therapeutic implications. A potential strategy for using cannabinoids for medical conditions without including the psychotropic effects may be achieved in several ways: one would be to identify the targeted compound(s) in the plant and then synthesize it in a way that will minimize psychoactive effects. Another approach is to trigger the peripheral endocannabinoid system as an alternative to cannabis use for medical purposes.
Another problem is the intake methods widely applied here in clinical trials -mostly by means of smoking, sometimes mixed with tobacco leaves. This means of delivery is highly undesirable, 252 Natural Product Communications Vol. 13 (3) 2018 Namdar and Koltai primarily in very young patients, but for the elderly as well. Other methods should be developed not only in order to facilitate the acceptance of treatment, but also to deliver the active compound directly to the desired organ and, thus, to enhance the therapeutic effect and enable dosage reduction. Another major shortcoming, as indicated above, is that the target compound (or compounds) and the accurate relative doses of the different cannabinoid compositions are yet unknown in most cases. The lack of knowledge regarding the pharmacokinetics of the different cannabinoids is also a major pitfall in the path to complete therapeutic efficacy. Designated clinical trials on multiple participants with as similar a condition as possible, along with more research regarding the effects of combinations of the different cannabnoid phytochemicals should overcome some of the aforementioned flaws.
